Delcath systems, Inc. · Transaction Jun 9, 2017 · Filed Aug 6, 2018 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · DCTH
0.00% · $0.0000 · Vol Not reported
Market closed · last close shown
Delcath Systems Inc
Health Care
$15.96
Follow $DCTH
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $DCTH by emailVeridion Score
BETAMEDIUM CONF · 5 of 6 factors measuredWed Sep 23 · last completed session · Pre-market · regular session opens 9:30 ET · DCTH
MethodologySentiment absence reason unknown
DCTH
Delcath Systems Inc
Wed Sep 23 · last completed session · Pre-market · regular session opens 9:30 ET
Middle range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
53/ 100
Veridion Score
Middle range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Wed Sep 23 · last completed session · Pre-market · regular session opens 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is DCTH moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Delcath Systems Inc
SURGICAL & MEDICAL INSTRUMENTS & APPARATUSListed since
2000
Employees
156
Country
US
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$15.96
Last session
Day high
$15.96
Last session
Day low
$15.96
Last session
Previous close
$15.96
52W high
$17.36
-8.06% from high
52W low
$8.19
85% of range
Market cap
$553.8M
P/E
1041.62×
EPS
$0.1300
Beta
0.58
Shares out
34.7M
Avg volume
438K
VWAP
$15.96
Last session
Price history computed in-house
1W
-1.78%
1M
-5.67%
3M
+23.34%
1Y
+44.70%
YTD
+58.02%
SMA 50 $15.18 · above
SMA 200 $11.68 · above
52W position 85%
DCTH overview
Related filings and maps
Public disclosures
Congress activity in DCTH
Official filing ↗
Federal contracts
DCTH contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for DCTH in this window.
Lobbying spend
DCTH lobbying filings, year to date.
Registered lobbying filings matched to Delcath Systems Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for DCTH in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for DCTH.
Options
Sovereign unlock shows live options positioning for DCTH.